Andrew Baum
Stock Analyst at Citigroup
(2.85)
# 1,708
Out of 4,859 analysts
63
Total ratings
72.09%
Success rate
12.35%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $80.32 | +4.58% | 14 | May 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $24.48 | +18.46% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $50.16 | +29.59% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $34.05 | +17.47% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $191.50 | +12.27% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $808.61 | +10.68% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $10.11 | -1.09% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $41.62 | - | 2 | Jul 5, 2017 |
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $80.32
Upside: +4.58%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.48
Upside: +18.46%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $50.16
Upside: +29.59%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $34.05
Upside: +17.47%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $191.50
Upside: +12.27%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $808.61
Upside: +10.68%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $10.11
Upside: -1.09%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $41.62
Upside: -